International Pharma Supplies Analytical Samples for Biosimilar Development Unlicensed Medicines Supplies Comparator Sourcing for clinical trials

International Pharma Supplies

We supply prescription only and OTC products to authorized wholesalers, licensed importers and aid organisations – from anywhere in the EU with a focus on German products.

Analytical Samples for Biosimilar Development

We supply analytical samples for Biosimilar development from almost anywhere in the world – Multi-country, Multi-batch and Multi-expiry date approach.

Unlicensed Medicines Supplies

We supply prescription only and OTC products to companies that have specialized in unlicensed medicines supplies, government agencies, hospitals and pharmacies.

Comparator Sourcing for clinical trials

We source Comparator products from almost anywhere in the World and have direct access to many innovators and approved supply sources.

Comparator Sourcing
for clinical trials

Analytical Samples for Biosimilar Development

Unlicensed Medicines Supplies

International
Pharma Supplies

Medizone Campaign – Comparator Sourcing – Clinical Trials Insight

Opening up new dimensions in comparator sourcing for clinical trials. Being a pioneer means having a vision. Medizone as a strategic comparator sourcing partner for clinical trials and specialist for ...

Medizone – Splendid similarities – WorldPharma | Comparator Sourcing

Recent MEDIZONE article - WorldPharma - Clinical Trials Insight "Splendid similarities The benefits of biosimilars have long been championed in the medical sector, but with their use set to increase in ...

Samsung Bioepis submits Enbrel biosimilar to EMA

Samsung Bioepis Co., Ltd., announced that the Marketing Authorization Application (MAA) for its Enbrel (etanercept) biosimilar candidate, SB4 has been validated and accepted for review by European Medicines ...

Ranbaxy launches first Biosimilar Infliximab in India!

Ranbaxy Laboratories Limited (Ranbaxy), one of India’s largest pharmaceutical company, announced on 1.12.2014 the launch of Infimab (BOW015), the first Remicade (infliximab) biosimilar in India. Infimab, ...

First Infliximab Biosimilar registered in India

EPIRUS Biopharmaceuticals, Inc. announced that it has received final marketing and manufacturing approvals for its Remicade (infliximab) biosimilar, BOW015, from the Drug Controller General of India (DCGI). ...

FDA Accepts Sandoz Application for Biosimilar Filgrastim

Sandoz, a Novartis Group company, has announced that FDA has accepted its Biologics Licence Application for filgrastim, which was filed under the new biosimilar pathway created in the Biologics Price ...

Consensus Document On Biosimilar Medicines Paper Is Now Available In Five Languages

Brussels, 25 June 2014 - After its successful launch in May 2013, the European Consensus Information Paper What you need to know about Biosimilar Medicinal Products is now available in English, French, German, ...

Falsified / stolen pharmaceutical products circulate in Germany!

German authorities are investigating currently the incidence of falsified / stolen Biopharmaceutical products originating from Italy. According to a BKA spokesperson six products are under scrutiny – ...

Biocad’s biosimilar rituximab receives approval in Russia

The rituximab biosimilar which will be marketed under the trade name AcellBia, is the first mAb biosimilar to receive positive opinion from the Russian regulatory body. The Russian MoH’s positive opinion ...

EUDRA GMDP DATABASE

GMDP Database showing Certificates, Licenses and Non-Compliance. EudraGMP is the database of the European Community of manufacturing authorisations and of certificates of good manufacturing practice. The ...
Pages:123»